Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease

Journal of Neural Transmission

Volumn 109, Issue 12, 2002, Pages 1445-1452

  Widner, B ^a   Leblhuber, F ^b   Frick, B ^a   Laich, A ^a   Artner Dworzak, E ^a   Fuchs, Dietmar ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

Folate; Homocysteine; Neopterin; Parkinson's disease

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; NEOPTERIN;

ADULT; AGED; AMINO ACID METABOLISM; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYANOCOBALAMIN DEFICIENCY; FEMALE; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; NEOPTERIN; PARKINSON DISEASE; VITAMIN B 12;

EID: 0036921282     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-002-0758-8     Document Type: Article

References (28)

1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69: 1326-1329
2. 12 and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55: 1449-1455
3. Dudman NPB (1999) An alternative view of homocysteine. Lancet 354: 2072-2074
4. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S (1999) Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Int Med 131: 363-375
5. Fuchs D, Weiss G, Reibnegger G, Wachter H (1992) The role of neopterin as a monitor of cellular immune activation in transplanation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 29: 307-341
6. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak A, Leblhuber F (2001) Is hyperhomocysteinemia due to oxidative depletion of folate rather than insufficient dietary intake? Clin Chem Lab Med 39: 691-694
7. Gottsater A, Anwaar I, Eriksson KF, Mattiasson I, Lindgarde F (2000) Homocysteine is related to neopterin and endothelin-1 in plasma of subjects with disturbed glucose metabolism and reference subjects. Angiology 51: 489-497
8. Halliwell B (1989) Oxidants and the central nervous system: Some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand [Suppl] 126: 23-33
9. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Müller T (1998) Hyperhomocysteinaemia in Parkinson's disease. J Neurol 245: 811-812
10. Leblhuber F, Walli J, Jellinger K, et al. (1998) Activated immune system in patients with Huntington's disease. Clin Chem Lab Med 36: 747-750
11. Leblhuber F, Wall J, Demel U, Tilz GP, Widner B, Fuchs D (1999) Increased serum neopterin concentrations in patients with Alzheimer's disease. Clin Chem Lab Med 37: 429-431
12. Leblhuber F, Walli J, Artner-Dworzak E, et al. (2000) Hyperhomocysteinemia in dementia. J Neural Transm 107: 1469-1474
13. Ledochowski M, Murr C, Lass-Flörl C, Fuchs D (2001) Helicobacter pylori and neopterin. Pteridines 12: 126-129
14. McGeer EG, McGeer PL (1997) The role of the immune system in neurodegenerative disorders. Mov Disord 12: 855-858
15. Müller T (2001) Non-dopaminergic drug treatment of Parkinson's disease. Expert Opin Pharmacother 2: 557-572
16. Müller T, Werne B, Fowler B, Kuhn W (1999) Nigral endotherlial dysfunction, homocysteine, and Parkinson's disease. Lancet 354: 126-127
17. Olszewski AJ, McCully KS (1993) Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 14: 683-693
18. Powers RW, Evans RW, Majors AK, et al. (1998) Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 179: 1605-1611
19. Ratter F, Gassner C, Shatrov C, Lehmann V (1999) Modulation of tumor necrosis factor-alpha-mediated cytotoxicity by changes of the cellular methylation state: Mechanism and in vivo relevance. Int Immunol 11: 519-527
20. Selhub J, Jacques PF, Rosenberg IH, et al. (1999) Serum total homocysteine concentrations in the third national health and nutrition examination survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations. Ann Int Med 131: 331-339
21. Seshadri S, Beiser A, Selhub J, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476-483
22. Turgan N, Habif S, Parildar Z, et al. (2001) Association between homocysteine and neopterin in healthy subjects measured by a simple HPLC-fluorometric method. Clin Biochem 34: 271-275
23. Ueland PM, Refsum G, Stabler SP, Malinow MR, Andersson A, Allen RH (1993) Total homocysteine in plasma or serum: Methods and clinical application. Clin Chem 39: 1964-1979
24. Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Wachter H, Fuchs D (1998) Neopterin: Indicator of oxidative stress and part of the cytotoxic armature of activated macrophages in humans. Pteridines 9: 91-102
25. Widner B, Fuchs D, Leblhuber F, Sperner-Unterweger B (2001) Does disturbed homocysteine and folate metabolism in depression result from enhanced oxidative stress? J Neurol Neurosurg Psychiatry 70: 419
26. Widner B, Leblhuber F, Fuchs D (2002) Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm 109: 181-189
27. Wiesli P, Maly FE, Meniconi A, et al. (2001) Chlamydia pneumoniae seropositivity and hyperhomocysteinemia are linked in patients with atherosclerosis. Clin Chem 47: 1304-1306
28. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K (2000) Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55: 437-440